Here are the top 5 articles detailing the advancements in hematologic oncology from 2025. BTK inhibitors have revolutionized ...
Eilean Therapeutics LLC has presented data for ZE74-0282, a novel small molecule that targets the JAK2 JH2 domain harboring the V617F mutation with no impact on wild-type JAK2.
Atavistik Bio’s $120 million Series B financing bolsters its push to advance first-in-class, allosteric small-molecule therapies for HHT and MPNs, leveraging its AMPS platform to selectively target ...
Proceeds will support the advancement of Atavistik Bio’s oral allosteric AKT1-selective inhibitor for Hereditary Hemorrhagic Telangiectasia (HHT) ...
Abstract: Most of the current research on dynamic multiobjective optimization problems (DMOPs) assumes that environmental changes can be detectable. However, undetectable changes are frequently ...
Eilean Therapeutics announced the advancement of ZE74-0282 into first-in-human clinical development. ZE74-0282 is a novel, ...
Researchers discovered that a tiny structural feature of the enzyme GPX4 helps keep neurons safe. A rare mutation removes this protection, allowing harmful molecules to damage cell membranes and ...
The JAK-STAT signaling pathway (Janus Kinase-Signal Transducer and Activator of Transcription) is a crucial molecular cascade that regulates immune responses, cell proliferation, and hematopoiesis.
Atavistik Bio to present the discovery and characterization of novel allosteric JAK2 V617F selective inhibitors that suppress mutant-dependent signaling and proliferation while sparing wild-type ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback